Bayer, Amgen Face Price Cuts as German Panel Expands Review

Bayer AG and Amgen Inc. are among drugmakers who may face price cuts as a German agency begins a broader review of the costs and benefits of medicines already on the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.